Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Tokai Pharmaceuticals Inc (NASDAQ: TKAI) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Tokai Pharmaceuticals Inc (NASDAQ: TKAI) concerning whether a series of statements by Tokai Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 2, 2015, an article titled "What's Wrong With Tokai Pharmaceuticals?" was published by Seeking Alpha. The article alleges "Tokai's attempt at a Phase 3 trial is based on data from just 6 patients out of 87 in Phase 2, based on after-the-fact cherry picking of data" and that "insider selling has been rampant ahead of the pivotal trial results in 2016."

Following this news, Tokai Pharmaceuticals Inc stock has fallen $0.59, or 5.34%, during intraday trading on November 2, 2015.

Based in Boston, Massachusetts, and founded in 2004 Tokai Pharmaceuticals Inc is a biopharmaceutical company, focusing on developing therapies for prostate cancer and other hormonally-driven diseases.

If you purchased shares of Tokai Pharmaceuticals Inc (NASDAQ: TKAI) on or before November 2, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185